



Modulation of inhibitory plasticity in basal ganglia output nuclei of patients with Parkinson's disease



Luka Milosevic^{a,b}, Robert Gramer^c, Tae Hyun Kim^d, Musleh Algarni^e, Alfonso Fasano^{e,f,i},
Suneil K. Kalia^{g,h,i}, Mojgan Hodaie^{g,h,i}, Andres M. Lozano^{g,h,i}, Milos R. Popovic^{a,b},
William D. Hutchison^{g,i,j,*}

^a Institute of Biomaterials and Biomedical Engineering, University of Toronto, Canada

^b Rehabilitation Engineering Laboratory, Toronto Rehabilitation Institute – University Health Network, Canada

^c Department of Neurosurgery, Duke University Medical Center, United States

^d Department of Human Biology, University of Toronto, Canada

^e Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – University Health Network, Canada

^f Division of Neurology, University of Toronto, Canada

^g Department of Surgery, University of Toronto, Canada

^h Division of Neurosurgery, Toronto Western Hospital – University Health Network, Canada

ⁱ Krembil Research Institute, Canada

^j Department of Physiology, University of Toronto, Canada

ARTICLE INFO

Keywords:

Basal ganglia
Deep brain stimulation
GABA
Globus pallidus
Levodopa
Parkinson's disease
Substantia nigra
Synaptic plasticity

ABSTRACT

Deep brain stimulation of certain target structures within the basal ganglia is an effective therapy for the management of the motor symptoms of Parkinson's disease. However, its mechanisms, as well as the pathophysiology of Parkinson's disease, are varied and complex. The classical model of Parkinson's disease states that symptoms may arise as a result of increased neuronal activity in the basal ganglia output nuclei due to down-regulated GABAergic striato-nigral/-pallidal projections. We sought to investigate the stimulation and levodopa induced effects on inhibitory synaptic plasticity in these basal ganglia output nuclei, and to determine the clinical relevance of altered plasticity with respect to patients' symptoms. Two closely spaced microelectrodes were advanced into the substantia nigra pars reticulata (potential novel therapeutic target for axial motor symptoms) or globus pallidus internus (conventional therapeutic target) in each of 28 Parkinson's disease patients undergoing subthalamic or pallidal deep brain stimulation surgery. Sets of 1 Hz test-pulses were delivered at different cathodal pulse widths (25, 50, 100, 150, 250 μ s) in randomized order, before and after a train of continuous high frequency stimulation at 100 Hz. Increasing the pulse width led to progressive increases in both the amplitudes of extracellular focally evoked inhibitory field potentials and durations of neuronal silent periods. Both of these effects were augmented after a train of continuous high frequency stimulation. Additionally, reductions in the baseline neuronal firing rate persisted beyond 1 min after high frequency stimulation. We found greater enhancements of plasticity in the globus pallidus internus compared to the substantia nigra pars reticulata, and that intraoperative levodopa administration had a potent effect on the enhancement of nigral plasticity. We also found that lower levels of nigral plasticity were associated with higher severity motor symptoms. The findings of this study demonstrate that the efficacy of inhibitory synaptic transmission may be involved in the pathophysiology of Parkinson's disease, and furthermore may have implications for the development of novel stimulation protocols, and advancement of DBS technologies.

1. Introduction

Parkinson's disease is characterized by a loss of dopaminergic innervation from the substantia nigra pars compacta (SNc) to the

striatum. This denervation is believed to cause increased neuronal activity within the inhibitory basal ganglia output nuclei, the substantia nigra pars reticulata (SNr) and globus pallidus internus (GPi) (Albin et al., 1989; Alexander and Crutcher, 1990; Delong, 1990). This occurs

* Corresponding author at: Toronto Western Hospital, University Health Network, MC12-417 – 399 Bathurst St, Toronto, Ontario M5T 2S8, Canada
E-mail address: whutch@uhnres.utoronto.ca (W.D. Hutchison).

<https://doi.org/10.1016/j.nbd.2018.10.020>

Received 14 September 2018; Received in revised form 17 October 2018; Accepted 31 October 2018

Available online 02 November 2018

0969-9961/ Crown Copyright © 2018 Published by Elsevier Inc. All rights reserved.

as a result of a loss of inhibitory tone on the subthalamic nucleus (STN) due to excessive striatal inhibition of the inhibitory globus pallidus externus (GPe) via the D2-receptor-mediated indirect pathway, and a concurrent reduced striatal inhibitory tone on the SNr and GPi via the D1-receptor-mediated direct pathway (Surmeier et al., 2007). These changes, as well as changes in firing patterns (Levy et al., 2002; Brown, 2003), are believed to give rise to the symptoms of Parkinson's disease.

Currently, dopamine replacement by levodopa administration remains the most effective therapy for the management of Parkinson's disease symptoms. However, long-term therapy is complicated by motor fluctuations and levodopa-induced dyskinesias, which represent a substantial source of disability in some patients (Nutt, 1990; Obeso et al., 2000). Subsequently, deep brain stimulation (DBS) of the STN or GPi has been widely adapted as a conventional alternative management option (Benabid et al., 1994; Limousin et al., 1995; Kumar et al., 1998, 2000; Kleiner-Fisman et al., 2006; Perlmutter and Mink, 2006; Lozano et al., 2017); as well as recent promising studies demonstrating the efficacy of SNr-DBS, or combined STN/SNr-DBS for the treatment of axial motor symptoms in Parkinson's disease (Chastan et al., 2009; Weiss et al., 2011a,b, 2013). DBS mimics the effect of beneficial lesions (Bergman et al., 1990; Aziz et al., 1991; Heywood and Gill, 1997) or inactivation by injections of muscimol and lidocaine (Wichmann et al., 1994; Levy et al., 2001), suggesting that DBS may work by inhibition of neuronal activity.

The precise physiological mechanisms that give rise to Parkinson's disease symptoms, as well as the therapeutic mechanisms of action of DBS are complex and varied, and the effects of pulse width on neuronal activity have not been systematically studied; although several clinical studies have suggested that varying the pulse width can impact outcome (Rizzone et al., 2001; Moro et al., 2002; Reich et al., 2015). In this intraoperative study, we investigated the effects of single pulses of electrical stimulation at different pulse widths on the neuronal activity and synaptic events at recording sites of the basal ganglia output nuclei (SNr and GPi), before and after a train of continuous high frequency stimulation (HFS). We employed a unique methodology for eliciting and measuring focal evoked potentials (fEPs) in SNr and GPi using two closely-spaced microelectrodes. Using this methodology, we have recently demonstrated that a train of continuous high frequency stimulation (HFS) is capable of inducing a robust potentiation of inhibitory synaptic plasticity within the SNr (Milosevic et al., 2017); here, we expand on this initial finding. The objectives of this study were to (i) investigate the pulse-width dependent effects of electrical stimulation on fEP amplitudes and neuronal firing at SNr and GPi recording sites, (ii) compare the changes in synaptic plasticity between the two output structures after a train of continuous HFS, (iii) investigate the effects of exogenous dopamine on synaptic plasticity in the SNr, and (iv) determine if a relationship exists between synaptic plasticity in the SNr and patients' axial motor symptoms. While it has been hypothesized that persistent changes to synaptic plasticity play a role in both adaptive and maladaptive responses to different forms of pathology and injury of the central nervous system (Kullmann et al., 2012), far less is known regarding the mechanisms of inhibitory (GABAergic) synaptic plasticity, compared to that evoked at excitatory synapses; especially within the human brain. The findings of this study demonstrate and implicate the involvement of inhibitory synaptic plasticity in Parkinson's disease, and furthermore may have implications for DBS programming, and advancement of DBS technologies.

2. Methods and materials

2.1. Patients

A total of 28 patients with Parkinson's disease undergoing microelectrode-guided placement of DBS electrodes into either the STN or GPi participated in this study, after overnight withdrawal from medication ("OFF"). In these patients, a total of 23 SNr recording sites (in 20

patients undergoing STN-DBS surgery) and 11 GPi recording sites (in 8 patients undergoing GPi-DBS surgery) were investigated. Seven of the (STN/) SNr patients were each given oral administration of 100 mg of levodopa (Sinemet 100/25) after completion of the recordings on the first side, thus, the second side was considered "ON" (i.e. an additional 7 recording sites were investigated ON medication). There was an average of 40 ± 3.5 min (mean \pm SEM) between levodopa administration and recording from the SNr on the second side. For each patient we determined the Unified Parkinson's Disease Rating Scale (UPDRS) III total motor subscore and axial subscore (sum of speech, facial expression, arising from chair, posture, gait, postural stability, body bradykinesia, and neck rigidity) in OFF and ON conditions. All of the conducted experiments conformed to the guidelines set by the Tri-Council Policy on Ethical Conduct for Research Involving Humans and were approved by the University Health Network Research Ethics Board. Furthermore, all of the patients in this study provided written, informed consent prior to taking part in the study.

2.2. Data acquisition

Two independently driven microelectrodes (25 μ m tip lengths, 600 μ m apart, 0.2–0.4 M Ω impedances, at 12.5 kHz), which share a common ground on a stainless-steel intracranial guidetube were used for recordings and microstimulation (Fig. 1A). Open filter recordings (5–3000 Hz) were amplified 5000 times using two Guideline System GS3000 amplifiers (Axon Instruments, Union City, USA), digitized using a CED 1401 data acquisition system (Cambridge Electronic Design, Cambridge, UK), and monitored using Spike2 software (Cambridge Electronic Design). Microstimulation was delivered using an isolated constant-current stimulator (Neuro-Amp1A, Axon Instruments) with biphasic pulses (cathodal followed by anodal).

2.3. Microelectrode recording procedures

Techniques for electrophysiological identification of STN/SNr (Hutchison et al., 1998) and GPi (Hutchison et al., 1994) have been previously published. Briefly, stereotactic coordinates of the anterior commissure and posterior commissures were determined using a T1-T2 fusion MRI (Signa, 1.5 T or 3 T, General Electric, Milwaukee, USA) on a surgical neuronavigation workstation (StealthStation, Medtronic, Minneapolis, USA). Additionally, estimation of the location of the STN ($x = 12$ mm lateral, $y = 3$ mm posterior to MCP, $z = 3$ mm inferior to AC-PC) or GPi ($x = 20$ mm lateral, $y =$ MCP, $z = 5$ mm inferior to AC-PC) was done based on the Schaltenbrand and Wahren (1977) standard atlas (Fig. 1B/C). Two microelectrodes were advanced in the dorso-ventral direction beginning 10 mm above the planned target. For STN/SNr trajectories, entry into the STN was confirmed based on an increase in background noise, and recording of single units with firing rates of approximately 20–40 Hz, irregular firing patterns with periods of beta activity, and kinesthetic single units. After 4–6 mm advancement, decreases in spike incidence signified exit from the ventral border of the STN and entry into the SNr was characterized by lower amplitude units with fast rates (80–100 Hz) and regular firing patterns. For GPi trajectories, recording sites were confirmed based on presence of irregular, high frequency discharge (50–90 Hz) neurons with responsiveness to movements, as well as border cells with highly regular 20–60 Hz firing rates. After 10–12 mm advancement, decreases in spike incidence signified exit from the ventral border, and the optic tract was confirmed based on visually evoked potentials elicited by brief flashes of light in the visual field as well as patients' reports of stimulation-induced phosphenes in the contralateral visual hemifield.

2.4. Stimulation protocol

At SNr or GPi recording sites, stimulation trains were delivered from a single microelectrode to elicit fEPs, which were recorded by the




Fig. 1. Microelectrode configuration, experimental recording locations, stimulation protocol, and sample data. (A) Custom dual-microelectrode assembly with $\sim 600\ \mu\text{m}$ mediolateral spacing. Representative (B) STN/SNr and (C) GPI microelectrode recording trajectories for electro-physiological mapping of the DBS target location. (D) Schematic of the stimulation protocol performed at SNr and GPI recording sites; five sets of 1 Hz (100 μA , 10s) “test-pulses” at different pulse widths (25, 50, 100, 150, 250 μs in randomized order) were delivered before and after HFS (100 Hz, 100 μA , 10s, 150 μs pulse width). (E) Sample data of a single pre- and post-HFS fEP and associated durations of neuronal inhibition (silent periods) elicited by a 50 μs pulse (left) and a 150 μs pulse (right) in the SNr. fEP amplitudes and silent periods were greater with larger pulse widths, and both variables were further enhanced after HFS. (F) Stimulation pulse width augmented the average latency of the return to baseline firing rate of neurons, before and after HFS. The graph depicts the poststimulus plot of firing rates at 10 ms intervals after stimulus delivery (omitted from graph for clarity: 25 μs and 100 μs pulse widths).

adjacent microelectrode (600 μm apart) at the same depth. Five sets of 1 Hz “test pulses” (100 μA for 10s; 10 pulses per set) were delivered at different cathodal pulse widths in randomized order (25, 50, 100, 150, 250 μs), separated by 5–10s. This was followed by a “long-train” of HFS (100 Hz, 100 μA , 150 μs pulse width, 10 s), followed by another five sets of post-HFS “test pulses” (see Fig. 1D). In the SNr OFF/ON levodopa patient subset, the first side was considered OFF, and the second side was considered ON. We have previously demonstrated that 1 Hz pulses do not elicit changes (neither increases nor decreases) to baseline fEP amplitudes in the SNr (Milosevic et al., 2018) or in the GPI (Liu et al., 2012), thus 1 Hz serves as a suitable “test pulse” frequency.

2.5. Offline analyses and statistics

A post-stimulus plot of the average firing rate of all SNr neurons was constructed (10 ms bins) to demonstrate the slow return to baseline firing with increasing pulse widths (only 50, 150, and 250 μs depicted for clarity), before and after HFS (Fig. 1F). We also calculated the percentage-reduction in the neuronal firing rate after completion of the stimulation protocol with respect to the pre-HFS baseline firing of the neuron (paired sample *t*-test, one-tailed). Amplitudes of the fEP were measured from the pre-stimulus baseline to the peak voltage deflections after each stimulation pulse (Prescott et al., 2008; Liu et al., 2012; Milosevic et al., 2017; see Fig. 1E). Pre- and post-HFS fEP amplitudes were normalized with respect to the average fEP amplitude of the pre-HFS 150 μs pulse width (i.e. all fEP measurements at a single recording site were divided by the average fEP amplitude of the pre-HFS 150 μs

pulse width train at the same recording site). The “silent period” was measured as the duration of neuronal inhibition after each stimulation pulse (i.e. between the stimulation pulse and the return of the first spike; see Fig. 1E). To measure the effects of pulse width and HFS on fEP amplitudes (Figs. 2A, 3A, B) as well as on silent periods (Fig. 2B), two-way repeated measures ANOVA (within subject factors) was used. Additionally, Pearson coefficients of correlation and *p*-values were obtained between normalized fEP amplitudes and silent periods pre- and post-HFS (Fig. 2C/D), at all recording sites where both fEPs and single units were measured. To determine whether there was a difference in the amount of plasticity after HFS between SNr OFF and SNr ON (Fig. 3A), two-way split-plot ANOVA was used (within subject factor: pulse width; between subject factor: medication) to compare the post-HFS amplitudes across pulse widths. The same (within subject factor: pulse width; between subject factor: location) was done to compare post-HFS fEP amplitudes between SNr OFF and GPI (Fig. 3B). All ANOVAs were followed up with posthoc pairwise comparison *t*-tests with Bonferroni correction. The data were not normally distributed and were log transformed prior to ANOVAs. The 25 μs pulse width often failed to elicit a measurable fEP (perhaps due to being below the threshold for activation, or the recording not being “focal” enough), thus was not included in ANOVAs (further, a value of zero cannot be log transformed). Additionally, we obtained Pearson coefficients of correlation between SNr plasticity (i.e. increase in normalized fEP amplitude, calculated as the average of the pre-HFS normalized fEP amplitude subtracted from the average post-HFS normalized fEP amplitude at the 150 μs pulse width), and both the UPDRSIII total motor subscore




Fig. 2. HFS-induced inhibitory synaptic plasticity in SNr (OFF), and pulse-width dependent effects. Larger stimulation pulse widths elicited larger (A) fEP amplitudes ($n_{\text{recording-sites}} = 23$), and longer (B) silent periods (durations of neuronal inhibition; $n_{\text{recording-sites}} = 13$) (mean \pm SEM). Furthermore, after a continuous 10s train of HFS, both fEP amplitudes and durations of neuronal inhibition were greater. Taken together, these findings are indicative of HFS-induced enhancement of inhibitory synaptic plasticity, which scaled with pulse width. For fEP amplitudes, we found significant main effects of both pulse width [$F(3,66) = 155.442$, $P < .001$] and HFS [$F(1,22) = 61.825$, $P < .001$]. Likewise for silent periods, we found significant main effects of pulse width [$F(3,36) = 27.291$, $P < .001$] and HFS [$F(1,12) = 28.647$, $P < .001$]. Detailed statistics can be found in Results section (*SNr plasticity OFF medication: fEP amplitudes and silent periods*). Further, larger fEP amplitudes were associated with longer durations of neuronal inhibition (silent periods). The silent period was linearly correlated with fEP amplitude both (C) pre-HFS ($P < .001$) and (D) post-HFS ($P < .001$). Again, fEP amplitudes and silent period durations scaled with the stimulation pulse width.

(Fig. 4A), and the axial symptom subscore (Fig. 4B). Furthermore, we plotted (as vectors) the changes that occurred to the enhancements of fEP amplitudes after intraoperative administration of levodopa and the changes that occurred to the clinical UPDRSIII total motor subscore (Fig. 4C) and axial motor subscore (Fig. 4D) from the OFF to ON medication state.

3. Results

3.1. SNr plasticity OFF medication: fEP amplitudes and silent periods

We found that at SNr recording sites, both fEP amplitudes (Fig. 2A) and durations of neuronal inhibition (silent periods; Fig. 2B) progressively increased as the pulse width was increased, and that measurements of both variables were greater after HFS (HFS-induced synaptic plasticity). For fEP amplitudes ($n_{\text{recording-sites}} = 23$) the main effects of pulse width [$F(3,66) = 155.442$, $P < .001$] and HFS [$F(1,22) = 61.825$, $P < .001$] were significant, with a significant interaction between the factors [$F(3,66) = 4.954$, $P < .01$]. Posthoc pairwise comparisons indicated significant ($P < .001$) differences across all pulse widths and pre-/post-HFS. For silent periods ($n_{\text{recording-sites}} = 13$), the main effects of pulse width [$F(3,36) = 27.291$,

$P < .001$] and HFS [$F(1,12) = 28.647$, $P < .001$] were also significant, with no interaction between factors. Posthoc pairwise comparisons indicated significant differences pre-/post-HFS ($P < .001$), and across all pulse widths ($P < .01$); except between 100 and 150 μs , and 150 and 250 μs . We further demonstrated that the fEP amplitudes and silent periods were positively correlated (i.e. a larger fEP led to a longer silent period) both pre-HFS ($R^2 = 0.1275$, $P < .001$; Fig. 2C) and post-HFS ($R^2 = 0.2810$, $P < .001$; Fig. 2D), and in both cases the effects scaled linearly with the pulse width. In Fig. 1F we demonstrated an increasingly delayed rate of recovery (from the “silent period”) of the firing rate ($n_{\text{recording-sites}} = 13$) after delivery of stimulation pulses (i.e. the neurons did not return to their baseline rate immediately after the “silent period,” but rather that there was a short latency “ramping” of activity). Furthermore, we found that after completion of the entire stimulation protocol, the average firing rate of all recorded neurons was reduced from 107.2 ± 10.0 Hz to 93.8 ± 12.3 Hz, therefore the neurons now fired at a new baseline that was only 87.5% ($P < .05$) of their pre-HFS baseline (measurements taken an average of 74 ± 5.3 s after HFS).




Fig. 3. (A) Effects of levodopa on SNr plasticity, and (B) differential modulation of plasticity between SNr and GPi OFF medication. Like SNr OFF medication, the fEP amplitudes in (A) SNr ON medication ($n_{\text{recording-sites}} = 7$), and in (B) GPi OFF ($n_{\text{recording-sites}} = 11$) increased as the pulse width was increased, and were further enhanced after HFS (mean \pm SEM). Our results also indicated that (A) levodopa further enhanced synaptic plasticity in the SNr, and that (B) synaptic plasticity in the GPi was greater than in SNr. 2-way split-plot ANOVAs comparing post-HFS fEP amplitudes between SNr OFF and (A) SNr ON, as well as comparing SNr OFF and (B) GPi OFF, revealed significant main effects of (A) medication [$F(1,28) = 5.354$, $P < .05$], and (B) location [$F(1,32) = 5.677$, $P < .05$]. Detailed statistics can be found in Results section (*Plasticity and levodopa (SNr OFF/ON): fEP amplitudes; Plasticity in different basal ganglia output nuclei (GPi/SNr OFF): fEP amplitudes*).

3.2. Plasticity and levodopa (SNr OFF/ON): fEP amplitudes

Like SNr OFF medication, we demonstrated that at SNr recording sites ON medication ($n_{\text{recording-sites}} = 7$) fEP amplitudes progressively increased as the pulse width was increased, and were larger after HFS (Fig. 3A). The main effects of pulse width [$F(3,18) = 43.512$, $P < .001$] and HFS [$F(1,6) = 14.224$, $P < .01$] were significant, with a significant interaction between factors [$F(3,18) = 5.439$, $P < .01$]. Posthoc pairwise comparisons indicated significant differences pre-/post-HFS ($P < .001$), and across all pulse widths ($P < .05$); except between 150 μs and 250 μs . Our results further imply that there was a greater synaptic potentiation at SNr recordings sites ON medication, compared to OFF medication. When comparing only post-HFS fEP amplitudes between SNr ON and SNr OFF, the main effect of medication [$F(1,28) = 5.354$, $P < .05$] was significant. The main effect of pulse width [$F(3,84) = 108.538$, $P < .001$] was also significant, with no interaction between factors. Post-hoc pairwise comparisons indicated significant ($P < .05$) differences across all pulse widths and ON/OFF medication.

3.3. Plasticity in different basal ganglia output nuclei (GPi/SNr OFF): fEP amplitudes

At GPi recording sites, fEP amplitudes also progressively increased as the pulse width was increased, and were larger after HFS ($n_{\text{recording-sites}} = 11$; Fig. 3B). The main effects of pulse width [$F(3,30) = 129.737$, $P < .001$] and HFS [$F(1,10) = 24.006$, $P = .001$] were significant, with no interaction between factors. Posthoc pairwise comparisons indicated significant ($P < .001$) differences across all pulse widths and pre-/post-HFS. Additionally, our results imply that there was a greater synaptic potentiation at GPi recordings sites, compared to SNr OFF medication. When comparing only post-HFS fEP amplitudes between GPi and SNr OFF, the main effect of location [$F(1,32) = 5.677$, $P < .05$] was significant, as was the main effect of pulse width [$F(3,96) = 193.059$, $P < .001$], with no interaction between factors. Post-hoc pairwise comparisons indicated significant ($P < .05$) differences across all pulse widths and between locations.

3.4. Clinical correlations

In Fig. 4A/B, we demonstrated that patients with higher severity UPDRSIII OFF medication scores had less plasticity (smaller increases in fEP amplitudes following HFS). Accordingly, we found significant inverse linear correlations between plasticity after HFS and both the UPDRSIII total motor subscore ($R^2 = 0.4766$, $P = .0015$; Fig. 4A) and axial subscore ($R^2 = 0.4303$, $P = .0031$; Fig. 4B). In Fig. 4C/D, we demonstrated the concurrent improvement of patients' clinical scores from OFF to ON medication and the increases in plasticity (in all but one patient) after oral administration of one tablet of Sinemet (100/25) in the ON/OFF patient subset. The average values of plasticity and symptom severity in OFF and ON conditions were calculated and displayed in each figure to demonstrate the mean improvement of both variables (bold arrow). The patient that did not have an increase in plasticity had the shortest time between levodopa administration and performing of the stimulation protocol on the second side (26 min), therefore there may not have been sufficient time to produce the ON condition (Lewitt et al., 2012; Hauser et al., 2018).

4. Discussion

One main finding of this study is that increasing the stimulation pulse width progressively increased both the amplitude of extracellular inhibitory fEPs, and the durations of neuronal inhibition in the SNr and GPi. The concurrent increases of these responses are indicative of a pulse-width-dependent membrane hyperpolarization, likely due to activation of presynaptic terminals and a consequent inhibitory response via GABA_A-mediated Cl^- influx (Dostrovsky et al., 2000; Wu et al., 2001; Filali et al., 2004; Lafreniere-Roula et al., 2010; Milosevic et al., 2017). Since increases in pulse width lead to a larger volume of tissue activation (Butson and McIntyre, 2008), the amount of the hyperpolarization likely increased due to activation of more inhibitory presynaptic terminals. While the fEP amplitudes continued to rise with the pulse width, the silent period appeared to plateau at 150 μs . The fEP is a continually increasing population response, while the silent period reflects the focal effects on a single neuron; and synaptically released neurotransmitters are known to saturate their receptors (Clements

UPDRSIII and SNr synaptic plasticity




Fig. 4. SNr synaptic plasticity and clinical symptom correlations. The top figures demonstrate that patients with higher severity UPDRSIII OFF medication scores had less plasticity. There were significant inverse linear correlations between the amount of synaptic plasticity (the average pre-HFS fEP amplitude subtracted from the average post-HFS fEP amplitude) and UPDRSIII (A) total motor subscore, and (B) axial symptoms subscore. The bottom figures demonstrate concurrent improvements in clinical symptom severity when the patients were ON, with increases in synaptic plasticity after administration of one tablet of Sinemet (100/25). The bold arrows represent the average changes (from OFF to ON) in both the amount of synaptic plasticity, and UPDRSIII (C) total motor subscore, and (D) axial symptoms subscore.

et al., 1996).

Our findings are consistent with the canonical findings of concurrent suppression of spontaneous neuronal activity with extracellularly recorded positive field potentials elicited by stimulation of caudato-nigral fibers in the substantia nigra of anesthetized cats (Yoshida and Precht, 1971). Precht and Yoshida (1971) also demonstrated the blockage of these responses by picrotoxin, implicating the involvement of GABA. Accordingly, histological findings have confirmed that the predominant afferent innervations of the SNr and GPI are the direct pathway GABAergic projections from the medium spiny neurons of the striatum (Ribak et al., 1979, 1981; Smith and Bolam, 1989; Rinvik and Ottersen, 1993; Shink and Smith, 1995; Parent and Hazrati, 1995a,b; Bolam et al., 2000; Smith et al., 2001). To a lesser extent, the afferents also include GABAergic projections from the GPe, and indirect pathway glutamatergic projections from the STN. Only ~10% of the total synapses on SNr somata are glutamatergic, while GABAergic projections account for the remaining ~90% (Rinvik and Ottersen, 1993; Parent and Hazrati, 1995b). While the stimulation pulses delivered in this study likely led to a nonspecific (Milosevic et al., 2017, 2018) activation of presynaptic terminals, the results appear to reflect the predominant GABAergic afferent innervation.

The other major novel findings of this study are the elucidations of HFS- and medication-induced enhancements of inhibitory synaptic plasticity (that also increased with the stimulation pulse width) which occurred after a train of continuous HFS. Enhancements of plasticity

were demonstrated by (i) increased fEP amplitudes after HFS, (ii) prolongation of neuronal silent periods after HFS, and (iii) a persistently reduced baseline neuronal firing rate after completion of the stimulation protocol. We found greater enhancements to the fEP amplitudes in the GPI compared to the SNr, and that levodopa administration (Sinemet 100/25) had a potent effect on the enhancement SNr fEP amplitudes. Furthermore, individuals with lower enhancements of SNr plasticity had more severe axial, and global motor symptoms. Perhaps increased plasticity acts as a compensatory mechanism (Bezard and Gross, 1998) in order to counteract the symptom-inducing loss of dopamine-mediated regulation of the direct and indirect pathways which project to the basal ganglia output structures (i.e., patients with greater plasticity are better able to regulate the strengths of the inputs to the SNr/GPI). While little is known about the mechanisms of inhibitory (GABAergic) synaptic plasticity, compared to excitatory (involving NMDA and AMPA receptors), there has been progress in this field of research in recent years (see reviews Castillo et al., 2011; Luscher et al., 2011; Kullmann et al., 2012). Potential mechanisms of inhibitory plasticity, the involvement of dopamine in plasticity, and the clinical/functional relevance of our findings are discussed below.

4.1. Mechanisms of inhibitory synaptic plasticity

While there are studies related to GABAergic long-term depression (LTD; ex. Lu et al., 2000; Wang et al., 2003), the focus of this discussion

will be on the mechanisms pertaining to the enhancement of GABAergic plasticity. Experimental studies (Clements, 1996) have demonstrated that synaptically released neurotransmitters saturate their receptors; subsequently, the functional strength of GABAergic synapses is proportional to the number of GABA_A receptors (GABA_ARs) on the postsynaptic membrane (Otis et al., 1994; Nusser et al., 1997). Recent research has demonstrated mechanisms of adjustment of GABAergic transmission, with a focus on GABA_AR-trafficking-mediated plasticity of inhibitory synapses (see Luscher et al., 2011). Indeed, Kittler et al. (2000) have demonstrated in hippocampal cell cultures that GABA_A receptors cycle between the synaptic membrane and intracellular sites, as a means of modulating inhibitory synaptic currents. Studies have revealed that overexpression of the GABA_AR associated protein (GABARAP; Wang et al., 1999; Chen and Olsen, 2007) facilitates the translocation of GABA_ARs to the cell surface of hippocampal neurons (Leil et al., 2004). A study by Marsden et al. (2007) demonstrated in rat slices that activation of NMDA receptors, that induces excitatory LTD through AMPA endocytosis, simultaneously increases the expression of GABA_ARs at the dendritic surface of hippocampal neurons; subsequently increasing amplitudes of miniature IPSPs. The study demonstrated that regulated trafficking of GABA_ARs was dependent on GABARAP, as well as on the glutamate receptor interacting protein (GRIP), and Ca²⁺ calmodulin dependent kinase II (CaMKII). This data reveals that bidirectional trafficking of AMPA receptors and GABA_ARs was driven by a single glutamatergic stimulation, which provided a potent postsynaptic mechanism for modulation of synaptic transmission (enhancement of inhibitory transmission).

It is possible then, that the stimulation-induced enhancements of inhibitory plasticity demonstrated in our study were also dependent on the presence and activation of glutamatergic subthalamic afferents of the indirect pathway. Although these glutamatergic afferents only account for ~10%, Marsden et al. (2010) demonstrated that only “moderate” chemical stimulation of NMDA receptors causes exocytosis of GABA_ARs and potentiation of miniature IPSCs. Under such conditions, CaMKII translocates to inhibitory (but not excitatory) synapses that trigger GABA_AR insertion and enhance inhibitory transmission. Following “strong” glutamatergic stimuli, CaMKII translocates to excitatory synapses inducing NMDA-receptor-dependent long-term potentiation (LTP). The selective targeting of CaMKII to glutamatergic or GABAergic synapses provides neurons with a mechanism whereby synaptic activity can selectively potentiate excitation or inhibition. In the context of our findings, this may explain why patients with less plasticity had more severe symptoms. The canonical parkinsonian basal ganglia model suggests that symptoms arise from more degenerated GABAergic (direct pathway), and more pronounced glutamatergic (indirect pathway) innervation of the basal ganglia output nuclei (SNr and GPI; Albin et al., 1989; Delong, 1990). Thus, less plasticity may be observed due to a “stronger” glutamatergic activation which may limit inhibitory potentiation, and would furthermore be associated with more severe symptoms.

Another form of inhibitory LTP has been described in the rat cerebellum at synapses between inhibitory stellate cells and Purkinje cells, termed rebound potentiation, which leads to a long-lasting (up to 75 min) potentiation of GABA_AR-mediated IPSCs (Kano et al., 1992; Hirano et al., 2016). Rebound potentiation is a heterosynaptic form of plasticity that is induced by depolarization of excitatory (glutamatergic) climbing fiber synapses. This activation causes an increase in extracellular Ca²⁺ concentration, and a subsequent activation of CaMKII, leading to an upregulation of postsynaptic GABA_AR function (Kawaguchi and Hirano, 2000, 2002, 2007; Kitagawa et al., 2009). While rebound potentiation has been found to be critically dependent on CaMKII-dependent alteration of GABARAP, and on GABARAP binding to GABA_ARs, it occurs without measurable changes in cellular distribution or surface expression of GABA_ARs (Kawaguchi and Hirano, 2007).

One of the first forms of short-term synaptic plasticity to be

described may also be relevant; post-tetanic potentiation. However, studies in this domain of research are limited to non-GABAergic synapses (ex. motor end-plates and neuromuscular junctions, calyx of Held, pyramidal neurons, etc.). Nevertheless, post-tetanic potentiation is described as a presynaptic form of synaptic enhancement that occurs after sustained high-frequency synaptic activation (Schlapfer et al., 1975; Baxter et al., 1985; Wojtowicz and Atwood, 1986; Zucker and Short-term synaptic plasticity, 1989; Zucker and Regehr, 2002; Balakrishnan et al., 2010). It can last several minutes, and becomes longer lasting when the stimulus frequency and duration are increased (Fioravante and Regehr, 2011). Post-tetanic potentiation is believed to work by increasing the probability of neurotransmitter release either as a result of an increase in Ca²⁺ influx (Habets and Borst, 2006), and/or by a protein kinase C (PKC)-dependent increase in the Ca²⁺ sensitivity of vesicle fusion (Korogod et al., 2007). Of particular relevance to our findings is that post-tetanic potentiation is often only observed following recovery from prolonged stimulation that is accompanied by synaptic depression (Borst et al., 1995; Zucker and Regehr, 2002). We have previously demonstrated (Milosevic et al., 2017) that indeed there is a rapid attenuation of fEPs that occurs during HFS at 100 Hz in the SNr (indicative of synaptic depression; also robustly observed in this study), after which synaptic potentiation occurs; while lower stimulation frequencies that failed to induce synaptic depression also failed to induce post-HFS potentiation.

In summary, although this intraoperative study performed in awake patients is limited by the inability to discern the exact cellular or synaptic mechanisms, the relevant literature in the field suggests that the enhancements of inhibitory plasticity may be a result of (i) an increase in GABA_AR expression at the postsynaptic cell surface, (ii) upregulated postsynaptic GABA_AR function (without changes in surface expression, i.e. rebound potentiation), and/or (iii) increased presynaptic neurotransmitter release properties (i.e. post-tetanic potentiation).

4.2. Dopamine and plasticity

It has been well established that dopaminergic regulation (or lack thereof) of neuronal activity of the basal ganglia direct and indirect pathways plays an important role in Parkinson's disease. As such, Barone et al. (1987) have provided direct evidence of the presence of D1 dopamine receptors in the terminals of striatal projections to both the SNr and entopeduncular nucleus (homologous to the primate GPI), with GABA being the main neurotransmitter of these projections (Scheel-Krüger, 1986). Rat brain slice studies (6-hydroxy-dopamine; 6-OHDA lesion) have indeed demonstrated that D1 receptor activation by endogenous dopamine (Aceves et al., 1995), exogenous dopamine (Florán et al., 1990), and dopamine synthesized from levodopa (Aceves et al., 1991) enhances GABA release from both striatal projections to the SNr and entopeduncular nucleus.

Thus, the finding of greater enhancements of SNr plasticity after administration of levodopa reflects this ability of levodopa to enhance striato-nigral inhibitory transmission, while the finding of greater enhancements of plasticity in the GPI compared to SNr (in the OFF medication condition) may reflect higher levels of endogenous dopamine at GPI terminals. Indeed, immunohistochemical studies have provided evidence that the primate GPI receives “massive” dopaminergic innervation (Parent and Smith, 1987; Lavoie et al., 1989).

Moreover, it has been demonstrated that D1 activation and the subsequent facilitated GABA release leads to enhancement of GABAergic IPSCs (Radnikow and Misgeld, 1998), as well as reductions in neuronal firing rates (Timmerman and Abercrombie, 1996) in SNr neurons. D1 receptor activity has been shown to be coupled with the formation of the secondary messenger cyclic adenosine monophosphate (cAMP) in the presynaptic terminals of SNr neurons (Jaber et al., 1996). Subsequently, Arias-Montaño et al. (2007) have demonstrated that cAMP formation leads to activation of protein kinase A (PKA), which enhances exocytosis of GABA vesicles by increased presynaptic Ca²⁺

Inhibitory frequency by temporal summation




Fig. 5. Proposed relationship between stimulation pulse width and frequency required for neuronal silencing. If a stimulation pulse is delivered just prior to the return of neuronal firing (i.e. at interstimulus intervals corresponding to the neuron's silent period), then complete neuronal inhibition would be achieved using the minimal possible stimulation frequency (i.e. complete neuronal inhibition by temporal summation of silent periods). (A) The figure demonstrates that after HFS, when inhibitory plasticity is enhanced, the duration of neuronal inhibition is prolonged, thus, the frequency required for complete neuronal inhibition (by temporal summation) can be reduced. This is representative data from one SNr recording site in a single patient. (B) The table displays the frequency required for complete inhibition of neuronal firing (by temporal summation) across all patients and all investigated pulse widths, before and after HFS. The values displayed are the inverses of the average silent period ($f_{\text{inhib.}} = 1/T_{\text{silent-period}}$) at each pulse width (from Fig. 2B). A hypothesis that stems from this study is that when a patient is ON medication, the frequency required for neuronal silencing after HFS would be lower than when they are OFF (bottom of B). This is assumed since we have demonstrated that levodopa enhances fEP amplitudes and that fEP amplitudes were correlated with silent periods.

influx through the involvement of P/Q-type voltage-activated Ca^{2+} channels.

4.3. Clinical and functional implications

The canonical parkinsonian “rate model” states that the output of the basal ganglia is increased due to a downregulation of the inhibitory striato-nigral/-pallidal projections of the direct pathway, and an upregulation of the excitatory subthalamo-nigral/-pallidal projections of the indirect pathway; due to a degenerated dopaminergic system. The net effect of this is greater downstream inhibition of the target motor areas which the basal ganglia output structures send their inhibitory projections to. Thus, our findings of lower levels of inhibitory plasticity being associated with more severe motor symptoms may be indicative of the overall levels of degeneration of the inhibitory direct pathway projections. Furthermore, these findings suggest that altered inhibitory plasticity within the basal ganglia may play a role in the pathophysiology of Parkinson's disease. Indeed, several studies have implicated altered plasticity in patients with Parkinson's disease (ex. Morgante et al., 2006; Ueki et al., 2006; Suppa et al., 2011; Prescott et al., 2014), and parkinsonian animal models (ex. Picconi et al., 2003, 2008). However, our findings demonstrate that HFS leads to a potentiation of the inhibitory direct pathway projections; and even more so after administration of levodopa. Enhancing the efficacy of the inhibitory projections would in turn adjust the synaptic weights of the inputs to the basal ganglia output structures (SNr and GPi), thus working to reduce their pathologically overactive output. While, current DBS delivery is continuous, we foresee that the enhancement of synaptic efficacy that occurs after HFS will become especially relevant in future applications of DBS with frequent OFF stimulation periods (i.e. closed-loop, intermittent, or cycling-DBS).

Although the SNr is not currently a conventional DBS target, studies (Chastan et al., 2008; Weiss et al., 2011a, 2013) have implicated it as an emerging complementary therapeutic target for the treatment of the axial motor symptoms of Parkinson's disease; including gait and balance disorders. Our clinical findings suggest that the SNr may indeed have a pathophysiological role in mediating axial motor symptoms. To that effect, Takakusaki et al. (2003) have demonstrated modulations of both postural muscle tone and locomotion induced by HFS (100 Hz) of the SNr in unanesthetized acutely decerebrate cats. Additionally, Burbaud et al. (1998) demonstrated that microinjections of GABA blockers into

the SNr of healthy primates led to severe axial postural anomalies, and Henderson et al. (2005) demonstrated that SNr lesions could reverse postural abnormalities in hemiparkinsonian (6-OHDA lesioned) primates (however, without improvements in bradykinesia). Indeed, GABAergic SNr efferents descend to the brainstem ponto-mesencephalic area, including the pedunculopontine nucleus and mesencephalic locomotor region which are known to be involved in locomotion and postural control (Aziz et al., 1998; Pahapill and Lozano, 2000; Takakusaki et al., 2003, 2005).

The results of this study furthermore have implications for a novel control parameter for closed-loop DBS; fEP amplitudes. Since the fEP amplitude scales with medication state, it may be able to inform the DBS system about ON/OFF fluctuations. The system would thereby be able to reduce stimulation intensity when the patient is ON, and increase it when they are OFF or experiencing peak-dosage levodopa induced-dyskinesias. Furthermore, fEP amplitudes can inform the system about the efficacy of the inhibitory synapses and selectively potentiate synapses by delivering a train of HFS. Although this would require a permanent embedded system to measure fEP amplitudes, DBS technologies are evolving more rapidly than ever (Arlotti et al., 2016). Russo et al. (2018) have demonstrated an efficacious implementation of closed-loop spinal cord stimulation which controls stimulation dose by measuring the recruitment of fibers in the dorsal column and by using the amplitude of evoked compound action potentials (ECAPs) to treat individuals with chronic pain.

Finally, in Fig. 5 we propose a relationship between the stimulation pulse width and frequency for achieving neuronal inhibition by temporal summation of the silent period. If a stimulation pulse is delivered at an interstimulus interval which corresponds to the neuron's silent period, then that neuron will not fire (i.e. one can discern the minimal stimulation frequency required for complete neuronal inhibition by temporal summation of silent periods; see Fig. 5A). With shorter pulse widths, higher stimulation frequencies are required to achieve neuronal silencing, whereas longer pulse widths require lower frequencies to achieve the same effect. By this principle, the enhancement of inhibitory synaptic efficacy can be utilized to reduce electrical energy; for example, the same stimulation frequency can be used with a pre-HFS pulse width of 150 μ s, as can be used with a post-HFS pulse width of 50 μ s (see Fig. 5B). This may have implications for moderating DBS side effects, for example, to compensate for sub-optimal electrode placements in order to reduce stimulation of surrounding structures or fibers.

Intermittently enhancing the efficacy of inhibitory synapses can allow for a reduction in the volume of tissue activation while maintaining neuronal inhibition, thereby having the potential to widen the therapeutic window (Reich et al., 2015). Finally, although this study did not directly determine chronaxie values by measuring threshold activations for each pulse width, chronaxies values for optimal DBS efficacy have been estimated to be about 130 μ s and 150 μ s for thalamic and pallidal stimulation, respectively (Holsheimer et al., 2000a; Holsheimer et al., 2000b), and these values were indeed those pulse widths showing the largest effects, above which the curves started to plateau.

4.4. Limitations

A limitation of the present intraoperative study was the inability to use pharmacological interventions to help elucidate specific molecular mechanisms, or the exact pre-/postsynaptic nature of the enhancement of synaptic plasticity. On the contrary, human studies have advantages over animal studies in that it is not known how well animal models correspond to human pathology, or anatomy. Furthermore, stimulation via microelectrodes elicits a smaller volume of tissue activation than that produced by macroelectrode stimulation; thus, the effects we report arise from activation of only a subset of target neurons (Maggio et al., 2010). In lieu of a control population, our study compared different anatomical locations (SNr/GPi), as well as different medication states (ON/OFF). Additional pragmatic limitations include the inability to obtain measurements of synaptic plasticity at the same recording location under both medication states, as well as the inability to discern the exact time course (duration) of the enhanced plasticity. This would excessively prolong intraoperative time; however, obtaining such measurements would be an interesting prospective study in an appropriate animal model. An additional prospective study would be to investigate the effects of levodopa on plasticity in the GPi and preform clinical correlations in a larger GPi patient cohort. Finally, a pragmatic limitation of intraoperative studies in humans would be.

5. Conclusions

We determined that increasing the pulse width led to concurrent increases in the amplitudes of inhibitory fEPs and the durations of neuronal silent periods in basal ganglia output nuclei. Both of these measured variables were enhanced after a train of continuous HFS, demonstrative of enhanced inhibitory synaptic transmission. We found greater enhancements in the GPi compared to the SNr, and that levodopa administration had a potent effect on the enhancement of SNr plasticity. Finally, we found that lower levels of SNr plasticity were associated with higher severity motor symptoms.

Acknowledgments

We thank the functional neurosurgical fellows (Robert Dallapiazza, Darren Lee, and Philippe De Vlooe) who assisted in the operations, and the patients who participated in this study.

Funding

This work was supported in part by the Natural Sciences and Engineering Research Council: Discovery Grant RGPIN-2016-06358 (M.R.P.), and the Dystonia Medical Research Foundation (W.D.H.).

Disclosures

A.F., S.K.K., M.H., A.M.L., and W.D.H. have received honoraria, travel funds, and/or grant support from Medtronic. A.F. received research grants, speaker and consultant honoraria from Boston Scientific. M.R.P. is a shareholder in MyndTec Inc. and an advisor to Myant Inc. A.M.L. is a co-founder of Functional Neuromodulation Ltd.

References

- Aceves, J., Floran, B., Martinez-Fong, D., Sierra, A., Hernandez, S., Mariscal, S., 1991 Jan 2. L-DOPA stimulates the release of [3H] γ -aminobutyric acid in the basal ganglia of 6-hydroxydopamine lesioned rats. *Neurosci. Lett.* 121 (1–2), 223–226.
- Aceves, J., Floran, B., Sierra, A., Mariscal, S., 1995 Sep 1. D-1 receptor mediated modulation of the release of γ -aminobutyric acid by endogenous dopamine in the basal ganglia of the rat. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 19 (5), 727–739.
- Albin, R.L., Young, A.B., Penney, J.B., 1989 Jan 1. The functional anatomy of basal ganglia disorders. *Trends Neurosci.* 12 (10), 366–375.
- Alexander, G.E., Crutcher, M.D., 1990 Jul 1. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. *Trends Neurosci.* 13 (7), 266–271.
- Arias-Montaño, J.A., Floran, B., Floran, L., Aceves, J., Young, J.M., 2007 May 1. Dopamine D1 receptor facilitation of depolarization-induced release of γ -aminobutyric acid in rat striatum is mediated by the cAMP/PKA pathway and involves P/Q-type calcium channels. *Synapse* 61 (5), 310–319.
- Arlotti, M., Rosa, M., Marceglia, S., Barbieri, S., Priori, A., 2016 Jul 31. The adaptive deep brain stimulation challenge. *Parkinsonism Relat. Disord.* 28, 12–17.
- Aziz, T.Z., Peggs, D., Sambrook, M.A., Crossman, A.R., 1991 Jan 1. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. *Mov. Disord.* 6 (4), 288–292.
- Aziz, T.Z., Davies, L., Stein, J., France, S., 1998 Jan 1. The role of descending basal ganglia connections to the brain stem in Parkinsonian akinesia. *Br. J. Neurosurg.* 12 (3), 245–249.
- Balakrishnan, V., Srinivasan, G., Von Gersdorff, H., 2010 Sep 1. Post-tetanic potentiation involves the presynaptic binding of calcium to calmodulin. *J. Gen. Physiol.* 136 (3), 243–245.
- Barone, P., Tucci, I., Parashos, S.A., Chase, T.N., 1987 Jun 12. D-1 dopamine receptor changes after striatal quinolinic acid lesion. *Eur. J. Pharmacol.* 138 (1), 141–145.
- Baxter, D.A., Bittner, G.D., Brown, T.H., 1985 Sep 1. Quantal mechanism of long-term synaptic potentiation. *Proc. Natl. Acad. Sci.* 82 (17), 5978–5982.
- Benabid, A.L., Pollak, P., Gross, C., Hoffmann, D., Benazzouz, A., Gao, D.M., Laurent, A., Gentil, M., Perret, J., 1994. Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. *Stereotact. Funct. Neurosurg.* 62 (1–4), 76–84.
- Bergman, H., Wichmann, T., DeLong, M.R., 1990 Sep 21. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. *Science* 249 (4975), 1436–1438.
- Bezard, E., Gross, C.E., 1998 Jun 1. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. *Prog. Neurobiol.* 55 (2), 93–116.
- Bolam, J.P., Hanley, J.J., Booth, P.A., Bevan, M.D., 2000 May. Synaptic organisation of the basal ganglia. *J. Anat.* 196 (4), 527–542.
- Borst, J.G., Helmchen, F., Sakmann, B., 1995 Dec 15. Pre- and postsynaptic whole-cell recordings in the medial nucleus of the trapezoid body of the rat. *J. Physiol.* 489 (3), 825–840.
- Brown, P., 2003 Apr 1. Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. *Mov. Disord.* 18 (4), 357–363.
- Burbaud, P., Bonnet, B., Guehl, D., Lagueny, A., Bioulac, B., 1998 Jan 5. Movement disorders induced by gamma-aminobutyric acid agonist and antagonist injections into the internal globus pallidus and substantia nigra pars reticulata of the monkey. *Brain Res.* 780 (1), 102–107.
- Butson, C.R., McIntyre, C.C., 2008 Jan 1. Current steering to control the volume of tissue activated during deep brain stimulation. *Brain Stimul. Basic Transl. Clin. Res. Neuromodul.* 1 (1), 7–15.
- Castillo, P.E., Chiu, C.Q., Carroll, R.C., 2011 Apr 1. Long-term plasticity at inhibitory synapses. *Curr. Opin. Neurobiol.* 21 (2), 328–338.
- Chastan, N., Westby, G.W., Yelnik, J., Bardin, E., Do, M.C., Agid, Y., Welter, M.L., 2008 Nov 11. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease. *Brain* 132 (1), 172–184.
- Chen, Z.W., Olsen, R.W., 2007 Jan 1. GABAA receptor associated proteins: a key factor regulating GABAA receptor function. *J. Neurochem.* 100 (2), 279–294.
- Clements, J.D., 1996 May 1. Transmitter timecourse in the synaptic cleft: its role in central synaptic function. *Trends Neurosci.* 19 (5), 163–171.
- DeLong, M.R., 1990 Jul 1. Primate models of movement disorders of basal ganglia origin. *Trends Neurosci.* 13 (7), 281–285.
- Scheel-Krüger, J., 1986. Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. *Acta Neurol. Scand.* 73 (Suppl No 107), 54.
- Dostrovsky, J.O., Levy, R., Wu, J.P., Hutchison, W.D., Tasker, R.R., Lozano, A.M., 2000 Jul 1. Microstimulation-induced inhibition of neuronal firing in human globus pallidus. *J. Neurophysiol.* 84 (1), 570–574.
- Filali, M., Hutchison, W.D., Palter, V.N., Lozano, A.M., Dostrovsky, J.O., 2004 Jun 1. Stimulation-induced inhibition of neuronal firing in human subthalamic nucleus. *Exp. Brain Res.* 156 (3), 274–281.
- Fioravante, D., Regehr, W.G., 2011 Apr 1. Short-term forms of presynaptic plasticity. *Curr. Opin. Neurobiol.* 21 (2), 269–274.
- Floran, B., Aceves, J., Sierra, A., Martinez-Fong, D., 1990 Aug 14. Activation of D1 dopamine receptors stimulates the release of GABA in the basal ganglia of the rat. *Neurosci. Lett.* 116 (1–2), 136–140.
- Habets, R.L., Borst, J.G., 2006 Dec. An increase in calcium influx contributes to post-tetanic potentiation at the rat calyx of Held synapse. *J. Neurophysiol.* 96 (6), 2868–2876.
- Hauser, R.A., Ellenbogen, A., Khanna, S., Gupta, S., Modi, N.B., 2018. Onset and Duration of Effect of Extended-Release Carbidopa-Levodopa in Advanced Parkinson's Disease. *Neuropsychiatric Disease and Treatment*. Vol. 14. pp. 839.
- Henderson, J.M., Stanic, D., Tomas, D., Patch, J., Horne, M.K., Bourke, D., Finkelstein,

- D.I., 2005 May 28. Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys. *Behav. Brain Res.* 160 (2), 267–276.
- Heywood, P., Gill, S.S., 1997 Oct 25. Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease. *Lancet* 350 (9086), 1224.
- Hirano, T., Yamazaki, Y., Nakamura, Y., 2016 Feb 1. LTD, RP, and motor learning. *Cerebellum* 15 (1), 51–53.
- Holsheimer, J., Demeulemeester, H., Nuttin, B., de Sutter, P., 2000 Deca. Identification of the target neuronal elements in electrical deep brain stimulation. *Eur. J. Neurosci.* 12 (12), 4573–4577.
- Holsheimer, J., Dijkstra, E.A., Demeulemeester, H., Nuttin, B., 2000 Apr 1b. Chronaxie calculated from current-duration and voltage-duration data. *J. Neurosci. Methods* 97 (1), 45–50.
- Hutchison, W.D., Lozano, A.M., Davis, K.D., Saint-Cyr, J.A., Lang, A.E., Dostrovsky, J.O., 1994 Jul. Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients. *Neuroreport* 5 (12), 1533–1537.
- Hutchison, W.D., Allan, R.J., Opitz, H., Levy, R., Dostrovsky, J.O., Lang, A.E., Lozano, A.M., 1998 Oct 1. Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. *Ann. Neurol.* 44 (4), 622–628.
- Jaber, M., Robinson, S.W., Missale, C., Caron, M.G., 1996 Jan 1. Dopamine receptors and brain function. *Neuropharmacology* 35 (11), 1503–1519.
- Kano, M., Rexhausen, U., Dreessen, J., Konnerth, A., 1992 Apr. Synaptic excitation produces a long-lasting rebound potentiation of inhibitory synaptic signals in cerebellar Purkinje cells. *Nature* 356 (6370), 601.
- Kawaguchi, S.Y., Hirano, T., 2000 Aug 1. Suppression of inhibitory synaptic potentiation by presynaptic activity through postsynaptic GABAB receptors in a Purkinje neuron. *Neuron* 27 (2), 339–347.
- Kawaguchi, S.Y., Hirano, T., 2002 May 15. Signaling cascade regulating long-term potentiation of GABAA receptor responsiveness in cerebellar Purkinje neurons. *J. Neurosci.* 22 (10), 3969–3976.
- Kawaguchi, S.Y., Hirano, T., 2007 Jun 20. Sustained structural change of GABAA receptor-associated protein underlies long-term potentiation at inhibitory synapses on a cerebellar Purkinje neuron. *J. Neurosci.* 27 (25), 6788–6799.
- Kitagawa, Y., Hirano, T., Kawaguchi, S.Y., 2009 Jan 1. Prediction and validation of a mechanism to control the threshold for inhibitory synaptic plasticity. *Mol. Syst. Biol.* 5 (1), 280.
- Kittler, J.T., Delmas, P., Jovanovic, J.N., Brown, D.A., Smart, T.G., Moss, S.J., 2000 Nov 1. Constitutive endocytosis of GABAA receptors by an association with the adaptin AP2 complex modulates inhibitory synaptic currents in hippocampal neurons. *J. Neurosci.* 20 (21), 7972–7977.
- Kleiner-Fisman, G., Herzog, J., Fisman, D.N., Tamma, F., Lyons, K.E., Pahwa, R., Lang, A.E., Deuschl, G., 2006 Jun 1. Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. *Mov. Disord.* 21 (S14).
- Korogod, N., Lou, X., Schneggenburger, R., 2007 Oct 2. Posttetanic potentiation critically depends on an enhanced Ca²⁺ sensitivity of vesicle fusion mediated by presynaptic PKC. *Proc. Natl. Acad. Sci.* 104 (40), 15923–15928.
- Kullmann, D.M., Moreau, A.W., Bakiri, Y., Nicholson, E., 2012 Sep 20. Plasticity of inhibition. *Neuron* 75 (6), 951–962.
- Kumar, R., Lozano, A.M., Kim, Y.J., Hutchison, W.D., Sime, E., Halket, E., Lang, A.E., 1998 Sep 1. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. *Neurology* 51 (3), 850–855.
- Kumar, R., Lang, A.E., Rodriguez-Oroz, M.C., Lozano, A.M., Limousin, P., Pollak, P., Benabid, A.L., Guridi, J., Ramos, E., Vandewalle, A., Caemaert, J., 2000. Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease. *Neurology* 55 (12), S34–S39 Suppl 6.
- Lafreniere-Roula, M., Kim, E., Hutchison, W.D., Lozano, A.M., Hodaie, M., Dostrovsky, J.O., 2010 Aug 1. High-frequency microstimulation in human globus pallidus and substantia nigra. *Exp. Brain Res.* 205 (2), 251–261.
- Lavoie, B., Smith, Y., Parent, A., 1989 Nov 1. Dopaminergic innervation of the basal ganglia in the squirrel monkey as revealed by tyrosine hydroxylase immunohistochemistry. *J. Comp. Neurol.* 289 (1), 36–52.
- Leil, T.A., Chen, Z.W., Chang, C.S., Olsen, R.W., 2004 Dec 15. GABAA receptor-associated protein traffics GABAA receptors to the plasma membrane in neurons. *J. Neurosci.* 24 (50), 11429–11438.
- Levy, R., Lang, A.E., Dostrovsky, J.O., Pahapill, P., Romas, J., Saint-Cyr, J., Hutchison, W.D., Lozano, A.M., 2001 Oct 1. Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. *Brain* 124 (10), 2105–2118.
- Levy, R., Hutchison, W.D., Lozano, A.M., Dostrovsky, J.O., 2002 Apr 1. Synchronized neuronal discharge in the basal ganglia of parkinsonian patients is limited to oscillatory activity. *J. Neurosci.* 22 (7), 2855–2861.
- Lewitt, P.A., Ellenbogen, A., Chen, D., Lal, R., McGuire, K., Zomorodi, K., Luo, W., Huff, F.J., 2012 May 1. Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. *Clin. Neuropharmacol.* 35 (3), 103–110.
- Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Le Bas, J.F., Perret, J.E., Benabid, A.L., Broussolle, E., 1995 Jan 14. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. *Lancet* 345 (8942), 91–95.
- Liu, L.D., Prescott, I.A., Dostrovsky, J.O., Hodaie, M., Lozano, A.M., Hutchison, W.D., 2012 Mar 28. Frequency-dependent effects of electrical stimulation in the globus pallidus of dystonia patients. *J. Neurophysiol.* 108 (1), 5–17.
- Lozano, A.M., Hutchison, W.D., Kalia, S.K., 2017 Jul 25. What have we learned about movement disorders from functional neurosurgery? *Annu. Rev. Neurosci.* 40, 453–477.
- Lu, Y.M., Mansuy, I.M., Kandel, E.R., Roder, J., 2000 Apr 1. Calcineurin-mediated LTD of GABAergic inhibition underlies the increased excitability of CA1 neurons associated with LTP. *Neuron* 26 (1), 197–205.
- Luscher, B., Fuchs, T., Kilpatrick, C.L., 2011 May 12. GABAA receptor trafficking-mediated plasticity of inhibitory synapses. *Neuron* 70 (3), 385–409.
- Maggio, F., Pasciuto, T., Paffi, A., Apollonio, F., Parazzini, M., Ravazzani, P., et al., 2010. Micro vs macroelectrode DBS stimulation: A dosimetric study. In: 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology, pp. 2057–2060.
- Marsden, K.C., Beattie, J.B., Friedenthal, J., Carroll, R.C., 2007 Dec 26. NMDA receptor activation potentiates inhibitory transmission through GABA receptor-associated protein-dependent exocytosis of GABAA receptors. *J. Neurosci.* 27 (52), 14326–14337.
- Marsden, K.C., Shemesh, A., Bayer, K.U., Carroll, R.C., 2010 Nov 23. Selective translocation of Ca²⁺/calmodulin protein kinase IIα (CaMKIIα) to inhibitory synapses. *Proc. Natl. Acad. Sci.* 107 (47), 20559–20564.
- Milosevic, L., Kalia, S.K., Hodaie, M., Lozano, A.M., Fasano, A., Popovic, M.R., Hutchison, W.D., 2017 Dec 11. Neuronal inhibition and synaptic plasticity of basal ganglia neurons in Parkinson's disease. *Brain* 141 (1), 177–190.
- Milosevic, L., Kalia, S.K., Hodaie, M., Lozano, A.M., Popovic, M.R., Hutchison, W.D., 1 Jul 2018. Physiological mechanisms of thalamic ventral intermediate nucleus stimulation for tremor suppression. *Brain* 141 (7), 2142–2155. <https://doi.org/10.1093/brain/awy139>.
- Morgante, F., Espay, A.J., Gunraj, C., Lang, A.E., Chen, R., 2006 Feb 13. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. *Brain* 129 (4), 1059–1069.
- Moro, E., Esselink, R.J., Xie, J., Hommel, M., Benabid, A.L., Pollak, P., 2002 Sep 10. The impact on Parkinson's disease of electrical parameter settings in STN stimulation. *Neurology* 59 (5), 706–713.
- Nusser, Z., Cull-Candy, S., Farrant, M., 1997 Sep 1. Differences in synaptic GABAA receptor number underlie variation in GABA mini amplitude. *Neuron* 19 (3), 697–709.
- Nutt, J.G., 1990 Feb 1. Levodopa-induced dyskinesia Review, observations, and speculations. *Neurology* 40 (2), 340.
- Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., Lanciego, J.L., Artieda, J., Gonzalo, N., Olanow, C.W., 2000 Oct 1. Pathophysiology of the basal ganglia in Parkinson's disease. *Trends Neurosci.* 23, S8–19.
- Otis, T.S., De Koninck, Y., Mody, I., 1994 Aug 2. Lasting potentiation of inhibition is associated with an increased number of gamma-aminobutyric acid type A receptors activated during miniature inhibitory postsynaptic currents. *Proc. Natl. Acad. Sci.* 91 (16), 7698–7702.
- Pahapill, P.A., Lozano, A.M., 2000 Sep 1. The pedunculo-pontine nucleus and Parkinson's disease. *Brain* 123 (9), 1767–1783.
- Parent, A., Hazrati, L.N., 1995 Jn 1a. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. *Brain Res. Rev.* 20 (1), 91–127.
- Parent, A., Hazrati, L.N., 1995 Jan 1b. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. *Brain Res. Rev.* 20 (1), 128–154.
- Parent, A., Smith, Y., 1987 Dec 15. Organization of efferent projections of the subthalamic nucleus in the squirrel monkey as revealed by retrograde labeling methods. *Brain Res.* 436 (2), 296–310.
- Perlmutter, J.S., Mink, J.W., 2006 Jul 21. Deep brain stimulation. *Annu. Rev. Neurosci.* 29, 229–257.
- Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M.A., Calabresi, P., 2003 May. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. *Nat. Neurosci.* 6 (5), 501.
- Picconi, B., Paillé, V., Ghiglieri, V., Bagetta, V., Barone, I., Lindgren, H.S., Bernardi, G., Cenci, M.A., Calabresi, P., 2008 Feb 1. L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. *Neurobiol. Dis.* 29 (2), 327–335.
- Precht, W., Yoshida, M., 1971 Sep 10. Blockage of caudate-evoked inhibition of neurons in the substantia nigra by picrotoxin. *Brain Res.* 32 (1), 229–233.
- Prescott, I.A., Dostrovsky, J.O., Moro, E., Hodaie, M., Lozano, A.M., Hutchison, W.D., 2008 Dec 2. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. *Brain* 132 (2), 309–318.
- Prescott, I.A., Liu, L.D., Dostrovsky, J.O., Hodaie, M., Lozano, A.M., Hutchison, W.D., 2014 Nov 1. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia. *Neurobiol. Dis.* 71, 24–33.
- Radnikow, G., Mingseld, U., 1998 Mar 15. Dopamine D1 receptors facilitate GABAA synaptic currents in the rat substantia nigra pars reticulata. *J. Neurosci.* 18 (6), 2009–2016.
- Reich, M.M., Steigerwald, F., Sawalhe, A.D., Reese, R., Gunalan, K., Johannes, S., Nickl, R., Matthies, C., McIntyre, C.C., Volkmann, J., 2015 Apr 1. Short pulse width widens the therapeutic window of subthalamic neurostimulation. *Ann. Clin. Neurosci.* 2 (4), 427–432.
- Ribak, C.E., Vaughn, J.E., Roberts, E., 1979 Sep 15. The GABA neurons and their axon terminals in rat corpus striatum as demonstrated by GAD immunocytochemistry. *J. Comp. Neurol.* 187 (2), 261–283.
- Ribak, C.E., Vaughn, J.E., Barber, R.P., 1981 Jul 1. Immunocytochemical localization of GABAergic neurones at the electron microscopical level. *Histochem. J.* 13 (4), 555–582.
- Rinvik, E., Ottersen, O.P., 1993 Jan 1. Terminals of subthalamonigral fibres are enriched with glutamate-like immunoreactivity: an electron microscopic, immunogold analysis in the cat. *J. Chem. Neuroanat.* 6 (1), 19–30.
- Rizzone, M., Lanotte, M., Bergamasco, B., Tavella, A., Torre, E., Faccani, G., Melcangi, A., Lopiano, L., 2001 Aug 1. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: effects of variation in stimulation parameters. *J. Neurol. Neurosurg. Psychiatry* 71 (2), 215–219.
- Russo, M., Cousins, M.J., Brooker, C., Taylor, N., Boesel, T., Sullivan, R., Poree, L., Shariati, N.H., Hanson, E., Parker, J., 2018 Jan. Effective relief of pain and associated symptoms with closed-loop spinal cord stimulation system: preliminary results of the Avalon Study. *Neuromodul. Technol. Neural Interface* 21 (1), 38–47.

- Schaltenbrand, G., Wahren, W., 1977. Atlas for Stereotaxy of the Human Brain. Thieme-Verlag, Stuttgart.
- Schlapfer, W.T., Woodson, P.B., Smith, G.A., Tremblay, J.P., Barondes, S.H., 1975 Dec. Marked prolongation of post-tetanic potentiation at a transition temperature and its adaptation. *Nature* 258 (5536), 623.
- Shink, E., Smith, Y., 1995 Jul 17. Differential synaptic innervation of neurons in the internal and external segments of the globus pallidus by the GABA- and glutamate-containing terminals in the squirrel monkey. *J. Comp. Neurol.* 358 (1), 119–141.
- Smith, Y., Bolam, J.P., 1989 Jul 24. Neurons of the substantia nigra reticulata receive a dense GABA-containing input from the globus pallidus in the rat. *Brain Res.* 493 (1), 160–167.
- Smith, Y., Charara, A., Paquet, M., Kieval, J.Z., Paré, J.F., Hanson, J.E., Hubert, G.W., Kuwajima, M., Levey, A.I., 2001 Jul. Ionotropic and metabotropic GABA and glutamate receptors in primate basal ganglia. *J. Chem. Neuroanat.* 22 (1–2), 13–42.
- Suppa, A., Marsili, L., Belvisi, D., Conte, A., Iezzi, E., Modugno, N., Fabbri, G., Berardelli, A., 2011 Feb 1. Lack of LTP-like plasticity in primary motor cortex in Parkinson's disease. *Exp. Neurol.* 227 (2), 296–301.
- Surmeier, D.J., Ding, J., Day, M., Wang, Z., Shen, W., 2007 May 31. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. *Trends Neurosci.* 30 (5), 228–235.
- Takakusaki, K., Habaguchi, T., Ohtinata-Sugimoto, J., Saitoh, K., Sakamoto, T., 2003 Jun 18. Basal ganglia efferents to the brainstem centers controlling postural muscle tone and locomotion: a new concept for understanding motor disorders in basal ganglia dysfunction. *Neuroscience* 119 (1), 293–308.
- Takakusaki, K., Takahashi, K., Saitoh, K., Harada, H., Okumura, T., Kayama, Y., Koyama, Y., 2005 Nov 1. Orexinergic projections to the cat midbrain mediate alternation of emotional behavioural states from locomotion to cataplexy. *J. Physiol.* 568 (3), 1003–1020.
- Timmerman, W., Abercrombie, E.D., 1996 Aug 1. Amphetamine-induced release of dendritic dopamine in substantia nigra pars reticulata: D1-mediated behavioral and electrophysiological effects. *Synapse* 23 (4), 280–291.
- Ueki, Y., Mima, T., Ali Kotb, M., Sawada, H., Saiki, H., Ikeda, A., Begum, T., Reza, F., Nagamine, T., Fukuyama, H., 2006 Jan. Altered plasticity of the human motor cortex in Parkinson's disease. *Ann. Neurol.* 59 (1), 60–71.
- Wang, H., Bedford, F.K., Brandon, N.J., Moss, S.J., Olsen, R.W., 1999 Jan. GABA A-receptor-associated protein links GABA A receptors and the cytoskeleton. *Nature* 397 (6714), 69.
- Wang, J., Liu, S., Haditsch, U., Tu, W., Cochrane, K., Ahmadian, G., Tran, L., Paw, J., Wang, Y., Mansuy, I., Salter, M.M., 2003 Feb 1. Interaction of calcineurin and type-A GABA receptor $\gamma 2$ subunits produces long-term depression at CA1 inhibitory synapses. *J. Neurosci.* 23 (3), 826–836.
- Weiss, D., Breit, S., Wächter, T., Plewnia, C., Gharabaghi, A., Krüger, R., 2011 Jun 1a. Combined stimulation of the substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait disturbance in Parkinson's disease. *J. Neurol.* 258 (6), 1183–1185.
- Weiss, D., Wächter, T., Meisner, C., Fritz, M., Gharabaghi, A., Plewnia, C., Breit, S., Krüger, R., 2011 Decb. Combined STN/SNr-DBS for the treatment of refractory gait disturbances in Parkinson's disease: study protocol for a randomized controlled trial. *Trials* 12 (1), 222.
- Weiss, D., Walach, M., Meisner, C., Fritz, M., Scholten, M., Breit, S., Plewnia, C., Bender, B., Gharabaghi, A., Wächter, T., Krüger, R., 2013 Jun 11. Nigral stimulation for resistant axial motor impairment in Parkinson's disease? A randomized controlled trial. *Brain* 136 (7), 2098–2108.
- Wichmann, T., Bergman, H., DeLong, M.R., 1994 Aug 1. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. *J. Neurophysiol.* 72 (2), 521–530.
- Wojtowicz, J.M., Atwood, H.L., 1986 Mar 1. Long-term facilitation alters transmitter releasing properties at the crayfish neuromuscular junction. *J. Neurophysiol.* 55 (3), 484–498.
- Wu, Y.R., Levy, R., Ashby, P., Tasker, R.R., Dostrovsky, J.O., 2001 Mar 1. Does stimulation of the GPI control dyskinesia by activating inhibitory axons? *Mov. Disord.* 16 (2), 208–216.
- Yoshida, M., Precht, W., 1971 Sep 10. Monosynaptic inhibition of neurons of the substantia nigra by caudatonigral fibers. *Brain Res.* 32 (1), 225–228.
- Zucker, R.S., et al., 1989. *Annu. Rev. Neurosci.* Mar;12 (1), 13–31.
- Zucker, R.S., Regehr, W.G., 2002 Mar. Short-term synaptic plasticity. *Annu. Rev. Physiol.* 64 (1), 355–405.